17-β-hydroxysteroid dehydrogenase type 1: Computational design of active site inhibitors targeted to the Rossmann fold

Chemico-Biological Interactions

Volumn 143-144, Issue , 2003, Pages 481-491

  Brown, William M ^a   Metzger IV, Louis E ^a   Barlow, Jeremy P ^b   Hunsaker, Lucy A ^a   Deck, Lorraine M ^b   Royer, Robert E ^a   Vander Jagt, David L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

17 Hydroxysteroid dehydrogenases type 1; Breast cancer; Gossypol derivatives; Inhibition; Rossmann fold

Indexed keywords

DINUCLEOTIDE; GOSSYPOL; NICOTINAMIDE; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 1; TESTOSTERONE 17BETA DEHYDROGENASE 1 INHIBITOR; UNCLASSIFIED DRUG;

BINDING SITE; CALCULATION; CONFERENCE PAPER; CONTROLLED STUDY; DISSOCIATION; DRUG DESIGN; DRUG INHIBITION; ENZYME MODIFICATION; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; PLACENTA;

17-HYDROXYSTEROID DEHYDROGENASES; BINDING SITES; ENZYME INHIBITORS; KINETICS;

EID: 0037325534     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(02)00184-9     Document Type: Conference Paper

References (29)

1. Peltoketo H., Vihko P., Vihko R. Regulation of estrogen action: role of 17 beta-hydroxysteroid dehydrogenases. Vit. Horm. 55:1999;353-398.
2. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr. Rev. 18:1997;281-305.
3. Tremblay M.R., Poirier D. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation. J. Steroid Biochem. Mol. Biol. 66:1998;179-191.
4. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78:1991;C113-C118.
5. Jornvall H., Persson B., Krook M., Atrian S., Gonzalez-Duarte R., Jeffery J., Ghosh D. Short-chain dehydrogenases/reductases (SDR). Biochemistry. 34:1995;6003-6013.
6. Jin J.Z., Lin S.X. Human estrogenic 17beta-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Biochem. Biophys. Res. Commun. 259:1999;489-493.
7. Luu-The V., Zhang Y., Poirier D., Labrie F. Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol. 55:1995;581-587.
8. Breton R., Housset D., Mazza C., Fontecilla-Camps J.C. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure. 4:1996;905-915.
9. Betz G. Reaction mechanism of 17-beta-estradiol dehydrogenase determined by equilibrium rate exchange. J. Biol. Chem. 246:1971;2063-2068.
10. Deck L.M., Royer R.E., Chamblee B.B., Hernandez V.M., Malone R.R., Torres J.E., Hunsaker L.A., Piper R.C., Makler M.T., Vander Jagt D.L. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J. Med. Chem. 41:1998;3879-3887.
11. Vander Jagt D.L., Deck L.M., Royer R.E. Gossypol: prototype of inhibitors targeted to dinucleotide folds. Curr. Med. Chem. 7:2000;479-498.
12. Yu Y., Deck J.A., Hunsaker L.A., Deck L.M., Royer R.E., Goldberg E., Vander Jagt D.L. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem. Pharmacol. 62:2001;81-89.
13. Royer R.E., Deck L.M., Campos N.M., Hunsaker L.A., Vander Jagt D.L. Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles. J. Med. Chem. 29:1986;1799-1801.
14. Deck L.M., Vander Jagt D.L., Royer R.E. Gossypol and derivatives: a new class of aldose reductase inhibitors. J. Med. Chem. 34:1991;3301-3305.
15. Royer R.E., Deck L.M., Vander Jagt T.J., Martinez F.J., Mills R.G., Young S.A., Vander Jagt D.L. Synthesis and anti-HIV activity of 1,1′-dideoxygossypol and related compounds. J. Med. Chem. 38:1995;2427-2432.
16. Yang F., Zhu D.W., Wang J.Y., Lin S.X. Rapid purification yielding highly active 17 beta-hydroxysteroid dehydrogenase: application of hydrophobic interaction and affinity fast protein liquid chromatography. J. Chromatogr. 582:1992;71-76.
17. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J. Comp. Chem. 19:1998;1639-1662.
18. Mazza C., Breton R., Housset D., Fontecilla-Camps J.C. Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 273:1998;8145-8152.
19. Mehler E.L., Solmajer T. Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng. 4:1991;903-910.
20. Rossmann M.G., Liljas A., Branden C.I., Banaszak L.J. Boyer P. The Enzymes. 1975;61-102 Academic Press, New York.
21. Wierenga R.K., De Maeyer M.C.H., Hol W.G.J. Interaction of pyrophosphate moieties with alpha-helixes in dinucleotide binding proteins. Biochemistry. 24:1985;1346-1357.
22. Bellamacina C.R. The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding proteins. FASEB J. 10:1996;1257-1269.
23. Carugo O., Argos P. NADP-dependent enzymes. II. Evolution of the mono- and dinucleotide binding domains. Proteins. 28:1997;29-40.
24. Liu S.Y., Rose Z.J., Chung Y.J., Hsiao C.D., Chang W.R., Kuo I., Perozich J., Lindahl R., Hempel J., Wang B.C. The first structure of an aldehyde dehydrogenase reveals novel interactions between NAD and the Rossmann fold. Nat. Struct. Biol. 4:1997;317-326.
25. Wilson D.K., Bohren K.M., Gabbay K.H., Quiocho F.A. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 257:1992;81-84.
26. Dunn C.R., Banfield M.J., Barker J.J., Higham C.W., Moreton K.M., Turgut-Balik D., Brady R.L., Holbrook J.J. The structure of lactate dehydrogenase from Plasmodium falciparum reveals a new target for anti-malarial design. Nat. Struct. Biol. 3:1996;912-915.
27. Arteaga C.L., Khuri F., Krystal G., Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin. Oncol. 29:2002;15-26.
28. Henderson I.C., Canellos G.P. Cancer of the breast: the past decade (first of two parts). N. Engl. J. Med. 302:1980;17-30.
29. Sasano H., Suzuki T., Takeyama J., Utsunomiya H., Ito K., Ariga N., Moriya T. 17-beta-Hydroxysteroid dehydrogenase in human breast and endometrial carcinoma: a new development in intracrinology. Oncology. 59:(Suppl. 1):2000;5-12.